Polyplus-transfection licenses ZNA (TM) oligonucleotide technology to metabion
News Mar 23, 2010
Under the terms of the license, metabion GmbH has acquired rights to manufacture and commercialize custom ZNA oligonucleotides for research and in vitro diagnostic applications. metabion GmbH will begin commercialization on March 22nd, 2010.
Zip Nucleic Acids (ZNA (TM)) are novel modified oligonucleotides that offer increased affinity for nucleic acids without reducing specificity. This brings several advantages: ZNAs improve the performance of molecular hybridization techniques such as PCR assays when used as primers or probes, ZNAs also increase the sensitivity of tests and the detection of mutations, in addition, ZNAs' performance compares favourably with the best modified oligonucleotides available in the market today, further, ZNAs have the distinct advantage of being easy to design and cost effective to produce.
"We are truly delighted to sign this agreement with metabion, a well-established dynamic oligonucleotide company in Europe," said Mark Bloomfield, CEO of Polyplus-transfection. "This licensing agreement will enable more members of the life science community to access our innovative ZNA technology."
"In line with our approach to intelligently and deliberately expand our oligonucleotide custom synthesis portfolio to bring ever increasing value to our customers, we see great potential for ZNA (TM) modified oligonucleotides due to the inherent (chemical) advantages they offer for state-of-the-art molecular biological applications," said Dr. Regina Bichlmaier, CEO at metabion. "Combining our own and our customers´ expertise, this new technology will contribute to increase R&D flexibility and progress."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.